vidarabine has been researched along with 2019 Novel Coronavirus Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsfouk, AA; Eissa, IH; Elkaeed, EB; Hafez, EE; Khalifa, MM; Metwaly, AM | 1 |
| Bearne, SL; Gillis, TD | 1 |
| Ata, O; Inci, TG; Kocer, S; Mutlu, O; Sariyer, E; Turgut-Balik, D; Ugurel, E; Ugurel, OM | 1 |
| Campbell, TB; Jagannath, S; Madduri, D; Neumann, F; Parekh, S; Petrocca, F | 1 |
| Bai, S; Cai, Z; Gong, J; Huang, H; Huang, T; Peng, Y; Xiong, G; Xiu, H; Zhang, G; Zhang, S | 1 |
5 other study(ies) available for vidarabine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Topics: Antiviral Agents; Binding Sites; Biological Products; COVID-19; COVID-19 Drug Treatment; Density Functional Theory; Humans; Ligands; Molecular Docking Simulation; S-Adenosylmethionine; SARS-CoV-2; Small Molecule Libraries; Vidarabine; Viral Regulatory and Accessory Proteins | 2021 |
Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2.
Topics: Antiviral Agents; COVID-19; Cytidine; Escherichia coli; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Vidarabine | 2022 |
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
Topics: Adenosine Monophosphate; Amino Acid Sequence; Betacoronavirus; Binding Sites; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Enzyme Inhibitors; Folic Acid; Genome, Viral; Glucosides; Humans; Methyltransferases; Molecular Docking Simulation; Mutation; Pandemics; Pneumonia, Viral; RNA Helicases; SARS-CoV-2; Stilbenes; Vidarabine; Viral Nonstructural Proteins | 2020 |
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Topics: Antibodies, Viral; B-Cell Maturation Antigen; Cough; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Cyclophosphamide; Disease Progression; Fever; Hospitalization; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; SARS-CoV-2; Vidarabine | 2021 |
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; COVID-19; COVID-19 Drug Treatment; Enzyme Induction; HEK293 Cells; HeLa Cells; Humans; Interferon Type I; Phosphorylation; Promoter Regions, Genetic; Receptors, Virus; STAT1 Transcription Factor; Vidarabine | 2021 |